Tone mix
Week by week 52 weeks
Share of Rapport Therapeutics, Inc. Common Stock's 118 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jun 9, 2025 · tone +100Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a Potential 214% Upside in CNS Disorder Treatments+78
- Week of Apr 6, 2026 · tone +100Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Brokerages+67
- Week of Nov 3, 2025 · tone 0Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update-66
- Week of Aug 4, 2025 · tone 0Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update-66
- Week of Jun 8, 2026 · tone +100BTIG Raises its Price Target on Rapport Therapeutics (RAPP)+60
- Week of Jul 7, 2025 · tone +100Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Uncovering A Potential 190% Upside In The Biotechnology Sector+57
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Rapport Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 7 | -14 |
| Last 30 sessions | 22 | +22 |
| Last 90 sessions | 34 | +32 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.dailypolitical.com · 1 outletRapport Therapeutics (NASDAQ:RAPP) Stock Price Target Lowered at GuggenheimNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Rapport Therapeutics (NASDAQ:RAPP) Stock Price Target Lowered at Guggenheim | www.dailypolitical.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletRapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPSPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPS | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletRapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business UpdateNeutral
- www.themarketsdaily.com · 1 outletContrasting Rapport Therapeutics (NASDAQ:RAPP) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update | www.manilatimes.net | 1 | Neutral |
| Contrasting Rapport Therapeutics (NASDAQ:RAPP) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletRapport Therapeutics to Participate in Upcoming Investor ConferencesNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Rapport Therapeutics to Participate in Upcoming Investor Conferences | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletRapport Therapeutics (NASDAQ: RAPP) director buys $20.36 million of stock via fundsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Rapport Therapeutics (NASDAQ: RAPP) director buys $20.36 million of stock via funds | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Rapport Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.